Dedicated to Diseases of Iron Metabolism
Abfero Pharmaceuticals Inc. develops best-in-class, oral iron chelator therapies for patients suffering from transfusion-related iron-overload, age-related macular degeneration and neurodegenerative disease.
Iron overload and iron chelation to treat it are of profound clinical importance. In certain conditions including b-thalassemia, sickle-cell anemia and myelodysplastic syndromes, patients are regularly transfused with red blood cells to correct anemia. The blood transfusions, while life-saving, result in a perilous situation wherein excess iron accumulates in the patient’s tissue. This iron must be removed or it will cause severe damage to the heart, liver, pancreas and other organs and, in time, lead to organ failure and death. For this reason, patients on maintenance transfusion therapy are always treated with a chelator in an effort to maintain their bodies in iron balance. Chelators are small molecules designed to selectively bind and remove metals from the body. Abfero’s lead clinical candidate, SP-420, is licensed from the laboratory of Prof. Ray Bergeron (University of Florida), the pre-eminent expert on iron chelators.
Our lead compound SP-420 has completed two Phase 1 safety studies. Abfero will be initiating Phase 2 efficacy studies in transfusion-related iron overload and age-related macular degeneration in 2018
Sign up to receive updates, news, and more.